copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
ZYPREXA (olanzapine) Label - Food and Drug Administration None with ZYPREXA monotherapy When using ZYPREXA and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax® (4) When using ZYPREXA in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products (4)
for intramuscular use powder, Olanzapine for Injection, When using olanzapine for injection in combination with lithium or valproate, the prescriber should refer to the Warnings and Precautions section of the package inserts for lithium or valproate [see Drug Interactions (7)]
ZYPREXA INTRAMUSCULAR- olanzapine injection, powder, for solution TYA . . . ZYPREXA (olanzapine) is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( , ) and Patient Counseling Information ( )] 5 15 1217 2 When using ZYPREXA and fluoxetine in combination, also refer to the Boxed Warning section of the package insert for Symbyax
Eli Lilly and Company Other Concomitant Drug Therapy: When using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products
Zyprexa (Eli Lilly and Company): FDA Package Insert ZYPREXA (olanzapine) is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5 1), Use in Specific Populations (8 5), and Patient Counseling Information (17)] When using ZYPREXA and fluoxetine in combination, also refer to the Boxed Warning section of the package insert for Symbyax
PV 5197 AMP ZYPREXA - Food and Drug Administration The following findings are based on premarketing trials of (1) oral olanzapine for schizophrenia, bipolar mania, a subsequent trial of patients having various psychiatric symptoms in association with Alzheimer’s disease, and premarketing combination trials, and (2) intramuscular olanzapine for injection in agitated patients with schizophrenia
NDC Package 0002-7597-01 Zyprexa Intramuscular The NDC Packaged Code 0002-7597-01 is assigned to a package of 1 vial in 1 carton 2 ml in 1 vial of Zyprexa Intramuscular, a human prescription drug labeled by Eli Lilly And Company The product's dosage form is injection, powder, for solution and is administered via intramuscular form This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per
PRODUCT MONOGRAPH - Eli Lilly and Company Patients receiving intramuscular olanzapine should be closely observed for hypotension including postural hypotension, bradyarrhythmia and or hypoventilation, particularly for the first 2 to 4 hours following injection